Nov 28, 2019:Bayer and Pharmaron jointly develop new molecular entities for veterinary medicines, this will include drug substance and drug product manufacturing to support Bayer’s research, development and commercialization needs.
The goal of Bayer and Pharmaron is to provide veterinarians, pet owners and farmers with modern therapies that address unmet medical needs of their animal patients.
Pharmaron will provide state-of-the-art CMC capabilities and resources to speed up the development of preclinical and clinical projects for Bayer Animal Health.
To offer a variety of future therapeutic options for diseases that still cannot be adequately treated today,they facilitate the exploration of the small molecule-based chemical space as small molecules have always been the backbone of innovative drugs in veterinary medicines. https://media.bayer.com/baynews/baynews.nsf/ID/4E1384544C3EEC21C12584BF0041B78C?OpenDocument
